KR101618037B1 - 항종양 활성이 있는 Ａｋｔ/ＰＫＢ 저해제 - Google Patents

항종양 활성이 있는 Ａｋｔ/ＰＫＢ 저해제 Download PDF

Info

Publication number
KR101618037B1
KR101618037B1 KR1020107002898A KR20107002898A KR101618037B1 KR 101618037 B1 KR101618037 B1 KR 101618037B1 KR 1020107002898 A KR1020107002898 A KR 1020107002898A KR 20107002898 A KR20107002898 A KR 20107002898A KR 101618037 B1 KR101618037 B1 KR 101618037B1
Authority
KR
South Korea
Prior art keywords
akt
cancer
api
tumor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107002898A
Other languages
English (en)
Korean (ko)
Other versions
KR20100066438A (ko
Inventor
진 큐. 청
메이 쑨
세드 엠. 셉티
Original Assignee
유니버시티 오브 사우스 플로리다
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 사우스 플로리다 filed Critical 유니버시티 오브 사우스 플로리다
Publication of KR20100066438A publication Critical patent/KR20100066438A/ko
Application granted granted Critical
Publication of KR101618037B1 publication Critical patent/KR101618037B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
KR1020107002898A 2007-07-12 2008-07-14 항종양 활성이 있는 Ａｋｔ/ＰＫＢ 저해제 Expired - Fee Related KR101618037B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94936507P 2007-07-12 2007-07-12
US60/949,365 2007-07-12

Publications (2)

Publication Number Publication Date
KR20100066438A KR20100066438A (ko) 2010-06-17
KR101618037B1 true KR101618037B1 (ko) 2016-05-04

Family

ID=40229514

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107002898A Expired - Fee Related KR101618037B1 (ko) 2007-07-12 2008-07-14 항종양 활성이 있는 Ａｋｔ/ＰＫＢ 저해제

Country Status (10)

Country Link
US (2) US8183249B2 (enExample)
EP (1) EP2173352B1 (enExample)
JP (1) JP5568471B2 (enExample)
KR (1) KR101618037B1 (enExample)
CN (1) CN101743007B (enExample)
AU (1) AU2008274956B2 (enExample)
BR (1) BRPI0815563A2 (enExample)
CA (1) CA2695330C (enExample)
MX (1) MX2010000474A (enExample)
WO (1) WO2009009793A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2576765C (en) * 2004-09-03 2013-05-28 Applied Research Systems Ars Holding N.V. Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
JP5568471B2 (ja) * 2007-07-12 2014-08-06 ユニヴァーシティ オブ サウス フロリダ 抗腫瘍活性を有するａｋｔ／ｐｋｂの阻害剤
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
JP2013537195A (ja) 2010-09-07 2013-09-30 ディエムアイ アクイジション コーポレイション 疾患の治療
WO2012158197A2 (en) * 2010-11-11 2012-11-22 Lyndor Biosciences L.L.C. Compounds useful as akt/pkb modulators and uses thereof
RS56759B2 (sr) 2011-04-01 2024-10-31 Genentech Inc Kombinacija akt inhibitor jedinjenja i abiraterona za upotrebu pri terapeutskim tretiranjima
RU2635193C2 (ru) * 2011-04-01 2017-11-09 Дженентек, Инк. Биомаркеры для прогнозирования чувствительности к противоопухолевой терапии
CN102225067B (zh) * 2011-04-29 2012-10-03 济南环肽医药科技有限公司 一种治疗胃癌的药物组合物
AU2012323320B2 (en) 2011-10-10 2017-05-11 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
AU2012328605B9 (en) 2011-10-28 2017-08-03 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
GB201207722D0 (en) * 2012-05-02 2012-06-13 Bergenbio As Method
KR101461626B1 (ko) * 2012-08-02 2014-11-28 서울대학교산학협력단 Ａｋｔ１ 억제제 및 소수성 항암제를 포함하는 항암용 약학적 조성물
WO2014074883A1 (en) * 2012-11-08 2014-05-15 Lyndor Biosciences L.L.C. Novel synthesis of ld101
WO2014145729A2 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
CN105764502A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群及其类似物及衍生物的治疗益处的组合方法
US9986375B2 (en) * 2014-02-12 2018-05-29 Google Llc Energy-efficient location determination
JP6723222B2 (ja) 2014-08-18 2020-07-15 アンピオ ファーマシューティカルズ，インコーポレイテッド 関節病態の治療
FR3033499A1 (fr) * 2015-03-11 2016-09-16 Centre Leon-Berard Composition pour le traitement des tumeurs neuroendocrines pancreatiques
WO2016209969A1 (en) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
CN114099681B (zh) * 2020-12-04 2023-03-10 周清华 Akt/stat3作为免疫检查点抑制剂的靶点的用途
WO2023168291A1 (en) * 2022-03-02 2023-09-07 Terremoto Biosciences, Inc. Covalent modifiers of akt1 and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093290A2 (en) 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP4407008B2 (ja) * 2000-05-11 2010-02-03 パナソニック株式会社 カラー画像形成装置
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
AU2005228410A1 (en) * 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
WO2008094321A2 (en) * 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
JP5568471B2 (ja) 2007-07-12 2014-08-06 ユニヴァーシティ オブ サウス フロリダ 抗腫瘍活性を有するａｋｔ／ｐｋｂの阻害剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093290A2 (en) 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Organic Chemistry, 1977, 42, 997-1000

Also Published As

Publication number Publication date
AU2008274956B2 (en) 2014-08-21
US20090028855A1 (en) 2009-01-29
US9359347B2 (en) 2016-06-07
WO2009009793A3 (en) 2009-03-26
CN101743007A (zh) 2010-06-16
US8183249B2 (en) 2012-05-22
AU2008274956A1 (en) 2009-01-15
EP2173352A4 (en) 2011-07-27
WO2009009793A2 (en) 2009-01-15
CA2695330A1 (en) 2009-01-15
JP2010533206A (ja) 2010-10-21
US20130034598A1 (en) 2013-02-07
KR20100066438A (ko) 2010-06-17
EP2173352A2 (en) 2010-04-14
CA2695330C (en) 2017-06-13
BRPI0815563A2 (pt) 2015-02-18
MX2010000474A (es) 2010-06-23
CN101743007B (zh) 2015-04-08
JP5568471B2 (ja) 2014-08-06
EP2173352B1 (en) 2016-09-07

Similar Documents

Publication Publication Date Title
KR101618037B1 (ko) 항종양 활성이 있는 Ａｋｔ/ＰＫＢ 저해제
US20090054415A1 (en) Combinations, methods and compositions for treating cancer
EP2968379B1 (en) Etoposide prodrugs for use in targeting cancer stem cells
JP2020517652A5 (enExample)
US20070281040A1 (en) Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
WO2023140846A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
US20220062291A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a) with reduced inhibitory activity targeted to the dopamine d2 receptor and accompanying toxicity
US9180118B2 (en) Thiadiazolidinone derivatives
JP2003535038A (ja) 蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
KR102823786B1 (ko) 조합 의약으로서 사용되는 ezh1/2 이중 저해제를 함유하는 의약 조성물
JP2014511839A (ja) 抗癌治療薬
US20230226061A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
WO2006024494A1 (en) Use of midostaurin for treating gastrointestinal stromal tumors
Cheng et al. Inhibitors of AKT/PKB with anti-tumor activity
Desai et al. 344 Pharmacological and pharmacokinetic profile of AI1008, a novel and potent inhibitor of abl-kinase activity
CN101198253A (zh) 治疗癌症的组合、方法和组合物
HK1220365B (en) Etoposide prodrugs for use in targeting cancer stem cells

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190503

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210429

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210429